The Worm That Outlived the Expectation
A pill already prescribed for high blood pressure made roundworms live longer, in living Caenorhabditis elegans worms, with a maximum mean lifespan increase of 19% compared to untreated controls, in a study published January 20, 2023, in Aging Cell.
The drug is rilmenidine, used to treat hypertension, with a side-effect profile the authors describe as rare and non-severe in clinical use. The research team, whose institutions include the University of Liverpool, ETH Zurich, and Harvard Medical School, gave the drug to C. elegans worms at a concentration of 200 μM. Treated worms lived longer, retained mobility better as they aged, became more resistant to heat stress, showed elevated autophagy, and accumulated fewer polyglutamine protein aggregates. The drug worked whether introduced at the L4 larval stage or on day 12 of adulthood, the old worms responded too.
One Receptor, One Switch, One Very Old Trick
C. elegans is a free-living soil nematode about 0.04 inches (1 mm) long. Its body is fully transparent, and between 60 and 80% of its genes have a counterpart in the human genome, which is why it has served as a standard model for aging research for decades.
Rilmenidine extended lifespan by binding to a single receptor called nish-1, the nematode version of the human imidazoline type 1 receptor. That binding triggers a gene-expression pattern closely resembling caloric restriction: the cell behaves as though food is scarce, though the animal has not changed what it eats.
The same research group found that mice treated with rilmenidine showed transcriptional changes in liver and kidney tissues matching patterns associated with caloric restriction. The appearance of a caloric-restriction-like signal above the invertebrate-vertebrate divide is significant, though the researchers describe the mouse tissue findings as preliminary.
The mechanism is not a single step. Autophagy was required for rilmenidine to extend lifespan, blocking autophagy blocked the longevity effect. The transcription factors FOXO/DAF-16 and NRF1,2,3/SKN-1 were also required. AMPK signaling was not. The drug additionally increased ERK activity in the worms, an effect that disappeared when nish-1 was deleted.
Delete the Switch, Lose the Magic. Restore It, Get It Back.
The team deleted nish-1 entirely from C. elegans worms and treated those worms with rilmenidine. The lifespan extension disappeared completely. They then restored nish-1 function in those same worms. The extra lifespan returned.
That pattern converts a statistical association into an identified mechanism: not “this drug correlates with longer life in worms,” but “this receptor is the essential mediator, confirmed by removal and reinsertion.” If nish-1 is the specific address at which rilmenidine acts, future drug design has a deliberate target rather than a diffuse pharmacological profile to chase.
You Probably Cannot Eat Your Way Out of Aging, But the Biology Assumed You Had To
One myth needs to be named precisely. Rilmenidine does not extend lifespan in C. elegans by making the worms eat less. The Bennett et al. 2023 paper controlled for this directly: rilmenidine treatment did not affect pharyngeal pumping, the muscular action worms use to feed. Treated animals and untreated controls ate at the same rate.
What the drug appears to do instead is reach the downstream biology of caloric restriction through the nish-1 receptor, bypassing the dietary trigger entirely. Treating calorically restricted C. elegans with rilmenidine produced no further lifespan increase. Treating worms with genetically reduced TORC1 function alongside rilmenidine produced the same non-additive result. The drug and the diet appear to converge on the same pathway.
Caloric restriction in humans is associated with side effects including hair thinning, dizziness, and brittle bones. Rilmenidine’s clinical side-effect profile, at doses studied for hypertension, is described by the researchers as rare and non-severe, the same biological destination, but a substantially different road.
What Remains Open After the 2023 Result
The researchers flag the distance between C. elegans and a human clinical result as explicitly open. The worm and Homo sapiens share a significant proportion of their genomes but are separated by an enormous span of evolutionary time. Transcriptional changes resembling caloric restriction were observed in mouse liver and kidney tissues, but whole-animal lifespan results in mice are not reported in the 2023 paper.
Rilmenidine’s safety profile has been characterized only in the context of treating hypertension. Whether the human ortholog of nish-1, designated IRAS, responds equivalently in mammalian systems has not been established. No human clinical trials of rilmenidine as a lifespan-extending agent had been reported at the time the paper was published, and the authors describe investigating further clinical applications as an intention, not an ongoing program.
The 2023 Aging Cell result is precise and reproducible: a 19% maximum mean lifespan increase in C. elegans, confirmed by a knockout-and-rescue experiment that identified the essential receptor, with preliminary caloric-restriction-like signals in mouse tissues. The mechanism is known. Everything between that mechanism and a human being is still a question.